PPM1D Mutations Are Oncogenic Drivers of De Novo Diffuse Midline Glioma Formation

The role of PPM1D mutations in de novo gliomagenesis has not been systematically explored. Here we analyze whole genome sequences of 170 pediatric high-grade gliomas and find that truncating mutations in PPM1D that increase the stability of its phosphatase are clonal driver events in 11% of Diffuse Midline Gliomas (DMGs) and are enriched in primary pontine tumors. Through the development of DMG mouse models, we show that PPM1D mutations potentiate gliomagenesis and that PPM1D phosphatase activity is required for in vivo oncogenesis. Finally, we apply integrative phosphoproteomic and functional genomics assays and find that oncogenic effects of PPM1D truncation converge on regulators of cell cycle, DNA damage response, and p53 pathways, revealing therapeutic vulnerabilities including MDM2 inhibition.

Citing Articles

Establishment of xenografts and methods to evaluate tumor burden for the three most frequent subclasses of pediatric-type diffuse high grade gliomas.

Balaguer-Lluna L, Olaciregui N, Aschero R, Resa-Pares C, Paco S, Cuadrado-Vilanova M J Neurooncol. 2025; .

PMID: 39961939 DOI: 10.1007/s11060-025-04954-w.

PPM1D activity promotes cellular transformation by preventing senescence and cell death.

Stoyanov M, Martinikova A, Matejkova K, Horackova K, Zemankova P, Burdova K Oncogene. 2024; 43(42):3081-3093.

PMID: 39237765 PMC: 11473410. DOI: 10.1038/s41388-024-03149-3.

Pediatric Hemispheric High-Grade Gliomas and H3.3-G34 Mutation: A Review of the Literature on Biological Features and New Therapeutic Strategies.

Bonada M, Pittarello M, De Fazio E, Gans A, Alimonti P, Slika H Genes (Basel). 2024; 15(8).

PMID: 39202398 PMC: 11353413. DOI: 10.3390/genes15081038.

Primary thyroid nuclear protein in testis carcinoma: a case report and literature review.

Cao J, Liu Y, Lu C Gland Surg. 2024; 13(6):1116-1125.

PMID: 39015712 PMC: 11247582. DOI: 10.21037/gs-24-77.

The Landscape of Pediatric High-Grade Gliomas: The Virtues and Pitfalls of Pre-Clinical Models.

Furst L, Roussel E, Leung R, George A, Best S, Whittle J Biology (Basel). 2024; 13(6).

PMID: 38927304 PMC: 11200883. DOI: 10.3390/biology13060424.

References

Love M, Huber W, Anders S . Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 2014; 15(12):550. PMC: 4302049. DOI: 10.1186/s13059-014-0550-8. View

Nikbakht H, Panditharatna E, Mikael L, Li R, Gayden T, Osmond M . Spatial and temporal homogeneity of driver mutations in diffuse intrinsic pontine glioma. Nat Commun. 2016; 7:11185. PMC: 4823825. DOI: 10.1038/ncomms11185. View

Mehta S, Huillard E, Kesari S, Maire C, Golebiowski D, Harrington E . The central nervous system-restricted transcription factor Olig2 opposes p53 responses to genotoxic damage in neural progenitors and malignant glioma. Cancer Cell. 2011; 19(3):359-71. PMC: 3070398. DOI: 10.1016/j.ccr.2011.01.035. View

Gallitto M, Lazarev S, Wasserman I, Stafford J, Wolden S, Terezakis S . Role of Radiation Therapy in the Management of Diffuse Intrinsic Pontine Glioma: A Systematic Review. Adv Radiat Oncol. 2019; 4(3):520-531. PMC: 6639749. DOI: 10.1016/j.adro.2019.03.009. View

Wu G, Broniscer A, McEachron T, Lu C, Paugh B, Becksfort J . Somatic histone H3 alterations in pediatric diffuse intrinsic pontine gliomas and non-brainstem glioblastomas. Nat Genet. 2012; 44(3):251-3. PMC: 3288377. DOI: 10.1038/ng.1102. View

Verreault M, Schmitt C, Goldwirt L, Pelton K, Haidar S, Levasseur C . Preclinical Efficacy of the MDM2 Inhibitor RG7112 in MDM2-Amplified and TP53 Wild-type Glioblastomas. Clin Cancer Res. 2015; 22(5):1185-96. PMC: 4842012. DOI: 10.1158/1078-0432.CCR-15-1015. View

Ran F, Hsu P, Wright J, Agarwala V, Scott D, Zhang F . Genome engineering using the CRISPR-Cas9 system. Nat Protoc. 2013; 8(11):2281-2308. PMC: 3969860. DOI: 10.1038/nprot.2013.143. View

Dubois F, Shapira O, Greenwald N, Zack T, Wala J, Tsai J . Structural variants shape driver combinations and outcomes in pediatric high-grade glioma. Nat Cancer. 2022; 3(8):994-1011. PMC: 10365847. DOI: 10.1038/s43018-022-00403-z. View

Ghandi M, Huang F, Jane-Valbuena J, Kryukov G, Lo C, McDonald 3rd E . Next-generation characterization of the Cancer Cell Line Encyclopedia. Nature. 2019; 569(7757):503-508. PMC: 6697103. DOI: 10.1038/s41586-019-1186-3. View

10.

Her N, Oh J, Oh Y, Han S, Cho H, Lee Y . Potent effect of the MDM2 inhibitor AMG232 on suppression of glioblastoma stem cells. Cell Death Dis. 2018; 9(8):792. PMC: 6052082. DOI: 10.1038/s41419-018-0825-1. View

11.

Lawrence M, Stojanov P, Polak P, Kryukov G, Cibulskis K, Sivachenko A . Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature. 2013; 499(7457):214-218. PMC: 3919509. DOI: 10.1038/nature12213. View

12.

Taylor K, Mackay A, Truffaux N, Butterfield Y, Morozova O, Philippe C . Recurrent activating ACVR1 mutations in diffuse intrinsic pontine glioma. Nat Genet. 2014; 46(5):457-461. PMC: 4018681. DOI: 10.1038/ng.2925. View

13.

Fons N, Sundaram R, Breuer G, Peng S, McLean R, Kalathil A . PPM1D mutations silence NAPRT gene expression and confer NAMPT inhibitor sensitivity in glioma. Nat Commun. 2019; 10(1):3790. PMC: 6706443. DOI: 10.1038/s41467-019-11732-6. View

14.

Zhang L, Chen L, Wan H, Yang R, Wang Z, Feng J . Exome sequencing identifies somatic gain-of-function PPM1D mutations in brainstem gliomas. Nat Genet. 2014; 46(7):726-30. PMC: 4073211. DOI: 10.1038/ng.2995. View

15.

Li H, Durbin R . Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics. 2009; 25(14):1754-60. PMC: 2705234. DOI: 10.1093/bioinformatics/btp324. View

16.

Shadforth I, Dunkley T, Lilley K, Crowther D, Bessant C . Confident protein identification using the average peptide score method coupled with search-specific, ab initio thresholds. Rapid Commun Mass Spectrom. 2005; 19(22):3363-8. DOI: 10.1002/rcm.2203. View

17.

Patel S, Hartley R, Wei X, Furnish R, Escobar-Riquelme F, Bear H . Generation of diffuse intrinsic pontine glioma mouse models by brainstem-targeted in utero electroporation. Neuro Oncol. 2019; 22(3):381-392. PMC: 7442382. DOI: 10.1093/neuonc/noz197. View

18.

Brinkman E, Chen T, Amendola M, van Steensel B . Easy quantitative assessment of genome editing by sequence trace decomposition. Nucleic Acids Res. 2014; 42(22):e168. PMC: 4267669. DOI: 10.1093/nar/gku936. View

19.

Krug K, Mertins P, Zhang B, Hornbeck P, Raju R, Ahmad R . A Curated Resource for Phosphosite-specific Signature Analysis. Mol Cell Proteomics. 2018; 18(3):576-593. PMC: 6398202. DOI: 10.1074/mcp.TIR118.000943. View

20.

Matsuoka S, Ballif B, Smogorzewska A, McDonald 3rd E, Hurov K, Luo J . ATM and ATR substrate analysis reveals extensive protein networks responsive to DNA damage. Science. 2007; 316(5828):1160-6. DOI: 10.1126/science.1140321. View